TipRanks
Advertisement
Advertisement

DE:PGF Stock Latest News

Protagonist Therapeutics announces $300M share repurchase program
The FlyProtagonist Therapeutics announces $300M share repurchase program
7d ago
JNJ
TAK
Protagonist Therapeutics: Buy Rating Reiterated as Mimrylo Approval De-Risks Lead Asset; $186 Price Target Unchanged
PremiumRatings
Protagonist Therapeutics: Buy Rating Reiterated as Mimrylo Approval De-Risks Lead Asset; $186 Price Target Unchanged
14d ago
PTGX
Protagonist Therapeutics price target raised to $190 from $178 at BMO Capital
PremiumThe Fly
Protagonist Therapeutics price target raised to $190 from $178 at BMO Capital
14d ago
TAK
PTGX
Protagonist Therapeutics price target raised to $180 from $153 at Barclays
PremiumThe Fly
Protagonist Therapeutics price target raised to $180 from $153 at Barclays
14d ago
PTGX
Protagonist Therapeutics price target raised to $182 from $175 at Citi
PremiumThe Fly
Protagonist Therapeutics price target raised to $182 from $175 at Citi
15d ago
PTGX
Protagonist Therapeutics price target raised to $170 from $165 at Citizens
PremiumThe FlyProtagonist Therapeutics price target raised to $170 from $165 at Citizens
15d ago
PTGX
Protagonist Therapeutics price target raised to $170 from $167 at H.C. Wainwright
Premium
The Fly
Protagonist Therapeutics price target raised to $170 from $167 at H.C. Wainwright
15d ago
TAK
PTGX
Protagonist Therapeutics: Rusfertide Approval and Partnered Pipeline Underpin Buy Rating, $173 Price Target Reaffirmed
Premium
Ratings
Protagonist Therapeutics: Rusfertide Approval and Partnered Pipeline Underpin Buy Rating, $173 Price Target Reaffirmed
15d ago
PTGX
Protagonist announces Takeda received U.S. FDA approval for MIMRYLO
PremiumThe Fly
Protagonist announces Takeda received U.S. FDA approval for MIMRYLO
16d ago
TAK
PTGX
Protagonist Therapeutics price target raised to $178 from $112 at BMO Capital
PremiumThe Fly
Protagonist Therapeutics price target raised to $178 from $112 at BMO Capital
29d ago
JNJ
PTGX
Protagonist Therapeutics price target raised to $170 from $145 at Truist
PremiumThe Fly
Protagonist Therapeutics price target raised to $170 from $145 at Truist
1M ago
PTGX
Protagonist Therapeutics price target raised to $173 from $118 at Wedbush
PremiumThe Fly
Protagonist Therapeutics price target raised to $173 from $118 at Wedbush
1M ago
JNJ
PTGX
Protagonist Therapeutics upgraded to Buy from Neutral at Goldman Sachs
PremiumThe FlyProtagonist Therapeutics upgraded to Buy from Neutral at Goldman Sachs
1M ago
PTGX
Protagonist Therapeutics price target raised to $175 from $130 at Citi
Premium
The Fly
Protagonist Therapeutics price target raised to $175 from $130 at Citi
1M ago
PTGX
Protagonist Therapeutics: Emerging Multi-Asset Revenue Streams and Robust Pipeline Drive Buy Rating Ahead of Rusfertide Approval
Premium
Ratings
Protagonist Therapeutics: Emerging Multi-Asset Revenue Streams and Robust Pipeline Drive Buy Rating Ahead of Rusfertide Approval
1M ago
PTGX
Protagonist Therapeutics price target raised to $173 from $116 at Clear Street
PremiumThe Fly
Protagonist Therapeutics price target raised to $173 from $116 at Clear Street
1M ago
PTGX
Protagonist Therapeutics: Diversified Pipeline Progress and Strong Cash Position Drive Buy Rating and Price Target Hike from $130 to $175
PremiumRatings
Protagonist Therapeutics: Diversified Pipeline Progress and Strong Cash Position Drive Buy Rating and Price Target Hike from $130 to $175
1M ago
PTGX
Protagonist Therapeutics price target raised to $153 from $151 at Barclays
PremiumThe Fly
Protagonist Therapeutics price target raised to $153 from $151 at Barclays
1M ago
PTGX
Protagonist Therapeutics reports Q2 EPS $2.29, consensus $1.93
PremiumThe Fly
Protagonist Therapeutics reports Q2 EPS $2.29, consensus $1.93
1M ago
PTGX
Protagonist Therapeutics Highlights ICOTYDE Launch and Rusfertide Deal
PremiumCompany AnnouncementsProtagonist Therapeutics Highlights ICOTYDE Launch and Rusfertide Deal
1M ago
8K
PTGX
Analyst Tara Bancroft Boosts Protagonist Therapeutics Price Target to $155 on Stronger Icotyde Royalty Outlook and Buy Rating
Premium
Ratings
Analyst Tara Bancroft Boosts Protagonist Therapeutics Price Target to $155 on Stronger Icotyde Royalty Outlook and Buy Rating
2M ago
PTGX
Protagonist Therapeutics price target raised to $165 from $137 at Citizens
Premium
The Fly
Protagonist Therapeutics price target raised to $165 from $137 at Citizens
2M ago
PTGX

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >